12:00 PM EST - Amorfix Life Sciences Ltd. : announced that the Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR), has signed an exclusive license with Amorfix for the use of their proprietary ProMIS technology in developing vaccines (active immunotherapy) for the treatment of diseases caused by the formation of misfolded prion (PrP). Amorfix Life Sciences Ltd.
shares T.AMF are trading down $0.025 at $0.22.
